Salary, Integrity and Selection of a New Chair for California’s $12 Billion Cell and Gene Therapy Enterprise
By David Jensen,
The California Stem Cell Report
| 05. 20. 2022
Photo by Giorgio Trovato on Unsplash
The directors of the $12 billion California stem cell agency are looking for a new chair who is both decisive and collaborative, passionate and inclusive. But at the top of the wish list is a person who is a pillar of integrity.
At least that is what a survey of the 35 board members showed today. The results were released this afternoon, less than one business day before the directors’ Governance Subcommittee takes up the matter of compensation and qualifications for the new chair.
The post carries a salary range that currently tops out at $566,500 annually. But that could be boosted by the directors of the California Institute for Regenerative Medicine (CIRM), as the agency is officially known. Also figuring into the salary is whether the post should be a full-time job.
The new chair will oversee CIRM during the next decade or so, a period in which its results are likely to determine whether it lives or dies. Depending on its pace of spending, the agency will run out of cash...
Related Articles
By Carl Zimmer, The New York Times | 10.20.2026
For the first time, scientists say they have used viruses designed by artificial intelligence to treat a human patient.
Researchers announced on Tuesday that they had administered the virus, known as a phage, to a patient suffering from a deadly...
By Noah Fromson, HealthLab | 10.19.2026
Gene therapy is no longer the future of medicine — it’s reality. Treatments that replace, silence or edit genes are already changing clinical care.
There are more than 6,000 rare genetic disorders but only a fraction currently have treatable targets...
By Roxanne Khamsi, The Atlantic | 10.16.2026
In recent months, news came out about several distressing cases that have underscored the risks of gene therapy, which delivers DNA to a patient’s cells to treat disease. All of these cases have one thing in common that’s not apparent...
By Rebecca Roberts, The Scientist | 10.11.2026
Heritable genome editing in human embryos is once again under intense scrutiny after the publication of an opinion piece in Trends in Genetics at the end of last month.1 In the paper, Cathy Tie, the founder and chief...